• Explore /
  • Poster
  • / A multicenter, single-arm, open-label trial of birociclib, a CDK4/6 inhibitor, as a single agent, in patients with refractory HR+/HER2- metastatic breast cancer.

A multicenter, single-arm, open-label trial of birociclib, a CDK4/6 inhibitor, as a single agent, in patients with refractory HR+/HER2- metastatic breast cancer.

Abstract Video & Slides Poster

Authors

null

Jiayu Wang

Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, China

Jiayu Wang , Qingyuan Zhang , Tao Sun , Huiping Li , Ying Cheng , Huihui Li , Zhongsheng Tong , Jingfen Wang , Wei Li , Xinhong Wu , Yuee Teng , Jing Cheng , Zhendong Chen , Zhengqiu Zhu , Chengkong Shi , Li Wang , Mingming Liu , Haiyan Xu , Xianghui Duan , Binghe Xu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Metastatic

Track

Breast Cancer

Sub Track

Hormone Receptor-Positive

Clinical Trial Registration Number

NCT04539496

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 1072)

DOI

10.1200/JCO.2023.41.16_suppl.1072

Abstract #

1072

Poster Bd #

293

Abstract Disclosures

Similar Posters

Poster

2024 ASCO Gastrointestinal Cancers Symposium

Amivantamab monotherapy in relapsed/refractory metastatic colorectal cancer: OrigAMI-1, an open-label, phase 1b/2 study.

Amivantamab monotherapy in relapsed/refractory metastatic colorectal cancer: OrigAMI-1, an open-label, phase 1b/2 study.

First Author: Paul Eliezer Oberstein

First Author: Candace Bavette Mainor

First Author: Timothy A. Yap

First Author: Manish R. Patel